WO2007036785A2 - Carbon-isotope monoxide labeling of daa1106 and its analogues to be used as tracers for a peripheral type benzodiazepine binding site - Google Patents
Carbon-isotope monoxide labeling of daa1106 and its analogues to be used as tracers for a peripheral type benzodiazepine binding site Download PDFInfo
- Publication number
- WO2007036785A2 WO2007036785A2 PCT/IB2006/002669 IB2006002669W WO2007036785A2 WO 2007036785 A2 WO2007036785 A2 WO 2007036785A2 IB 2006002669 W IB2006002669 W IB 2006002669W WO 2007036785 A2 WO2007036785 A2 WO 2007036785A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- ome
- scheme
- carbon
- analogues
- labeling
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 0 *c(cc1)cc(N)c1Oc1ccccc1 Chemical compound *c(cc1)cc(N)c1Oc1ccccc1 0.000 description 13
- AJSFENHGGIPKRE-UHFFFAOYSA-N CC(N(Cc(cccc1OC)c1OC)c(cc(cc1)Cl)c1Oc1ccccc1)=O Chemical compound CC(N(Cc(cccc1OC)c1OC)c(cc(cc1)Cl)c1Oc1ccccc1)=O AJSFENHGGIPKRE-UHFFFAOYSA-N 0.000 description 1
- KNQWOGWVUJOITC-UHFFFAOYSA-N CC(N(Cc1cc(OC)cc(OC)c1)c(cc(cc1)F)c1Oc1ccccc1)=O Chemical compound CC(N(Cc1cc(OC)cc(OC)c1)c(cc(cc1)F)c1Oc1ccccc1)=O KNQWOGWVUJOITC-UHFFFAOYSA-N 0.000 description 1
- OPNYLIYXMHUHJX-UHFFFAOYSA-N CC(N(Cc1cc(OC)cc(OC)c1)c(cccc1)c1Oc1ccccc1)=O Chemical compound CC(N(Cc1cc(OC)cc(OC)c1)c(cccc1)c1Oc1ccccc1)=O OPNYLIYXMHUHJX-UHFFFAOYSA-N 0.000 description 1
- CPPSVHVMUQXXNW-UHFFFAOYSA-N CCOc1c(CN(C(C)=O)c(cc(cc2)Cl)c2Oc2ccccc2)cccc1 Chemical compound CCOc1c(CN(C(C)=O)c(cc(cc2)Cl)c2Oc2ccccc2)cccc1 CPPSVHVMUQXXNW-UHFFFAOYSA-N 0.000 description 1
- QRQDEXRCOMVZIT-UHFFFAOYSA-N CCOc1c(CN(C(C)=O)c(cccc2)c2Oc2ccccc2)cccc1 Chemical compound CCOc1c(CN(C(C)=O)c(cccc2)c2Oc2ccccc2)cccc1 QRQDEXRCOMVZIT-UHFFFAOYSA-N 0.000 description 1
- DZLMFTBUQJPZAU-UHFFFAOYSA-N CC[O](C)c1c(CN(C(C)=O)c(cc(cc2)F)c2Oc2ccccc2)cccc1 Chemical compound CC[O](C)c1c(CN(C(C)=O)c(cc(cc2)F)c2Oc2ccccc2)cccc1 DZLMFTBUQJPZAU-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/001—Acyclic or carbocyclic compounds
Definitions
- the present invention relates to analogues of DAAl 106 and a carbonylation method of labeling DAAl 106 and its analogues by carbon-isotope monoxide in a palladium mediated carbonylation reaction for the study of the function of peripheral benzodiazepine receptors in the neuroinflammation of a patient.
- the synthetic routes for the preparation of precursor amines and reference compounds were also developed.
- PET Positron emission tomography
- the 11 C-labelled biologically interesting molecules are used as PET tracer for various biological investigations in vitro and in vivo.
- the demand for new method for the synthesis of labelled molecules is continuously increasing with increasing use of PET in medical and biomedical research as well as in various clinical applications.
- PET -tracer synthesis since biologically active substances often contain carbonyl groups or functionalities that can be derived from a carbonyl group.
- the syntheses are tolerant to most functional groups, which means that complex building blocks can be assembled in the carbonylation step to yield the target compound. This is particularly valuable in PET-tracer synthesis where the unlabeled substrates should be combined with the labeled precursor as late as possible in the reaction sequence, in order to decrease synthesis-time and thus optimize the uncorrected radiochemical yield.
- [ 11 C] carbon monoxide can be expected to give a very low yield or fail completely.
- high pressures can be utilized for increasing reaction rates and minimizing the amounts of reagents.
- One problem with this approach is how to confine the labeled precursor in a small high- pressure reactor.
- Another problem is the construction of the reactor. If a common column type of reactor is used (i.e. a cylinder with tubing attached to each end), the gas-phase will actually become efficiently excluded from the liquid phase at pressurization. The reason is that the gas-phase, in contracted form, will escape into the attached tubing and away from the bulk amount of the liquid reagent.
- the cold-trap technique is widely used in the handling of ⁇ C-labeled precursors, particularly in the case of [ 11 C] carbon dioxide.
- the procedure has, however, only been performed in one single step and the labeled compound was always released in a continuous gas-stream simultaneous with the heating of the cold- trap.
- the volume of the material used to trap the labeled compound has been relative large in relation to the system to which the labeled compound has been transferred.
- the option of using this technique for radical concentration of the labeled compound and miniaturization of synthesis systems has not been explored. This is especially noteworthy in view of the fact that the amount of a l ⁇ -labeled compound usually is in the range of 20-60 nmol.
- PBR peripheral benzodiazepine receptors
- PBR is expressed in most organs and its expression is reported to be increased in activated microglia in the brain.
- PBR ligands such as [ 11 C]PKl 1195 have been widely used for the in vivo imaging of PBRs, Id.
- analogue used throughout this invention is defined as a chemical compound that is structurally similar to DAAl 106 but differs in composition i.e. elements, functional groups.
- the present invention provides a method that relates to a carbonylation method for the labeling of DAAl 106 and making a library of analogues of this compound for finding Positron Emission Tomography (PET) tracers for the study of the function of peripheral benzodiazepine receptors (PBR) in the neuroinflammation of a patient.
- PET Positron Emission Tomography
- PBR peripheral benzodiazepine receptors
- the present invention depicts a method for labeling synthesis of a ligand and its analogues for a peripheral type bezodiazepine receptor, comprising: providing a carbon-isotope using a carbon-isotope monoxide in a palladium mediated carbonylation reaction; introducing a micro autoclave technique into said carbonylation reaction whereby converting the carbon-isotope monoxide to a crude product; flashing the crude product with nitrogen to remove furan residues and adding acetonitile whereby forming a resulting solution; and injecting the resulting soultion into a liquid chromatograph.
- R2 H, OMe
- R3 H, OMe wherein Rl is OMe, F, or hydrogen; R2 is hydrogen or OMe; and R3 is hydrogen or OMe.
- the present invention shows a method for labeling synthesis of precursors for N-(2,5-dimethoxybenzyl)-N-(5-fluoro-2-phenoxyphenyl) acetamide analogues, comprising the reaction performed by Scheme (4):
- R1 OMe or H
- R2 OMe or H
- R3 Ome or H wherein Rl is OMe or hydorgen; R2 is OMe or hydrogen; and R3 is OMe or hydrogen.
- Scheme (4) shows a method for labeling synthesis of reference compounds for iV-(2,5-dimethoxybenzyl)-iV-(5-fluoro-2-phenoxyphenyl) acetamide analogues, comprising the reaction performed by Scheme (5):
- Fig. 1 shows the different structures and composition make up of three peripheral benzodiazepine receptor (PBR) ligands, Ro5-4864, PKl 1195, and DAAl 106 that have been labeled with [ 11 C].
- PBR peripheral benzodiazepine receptor
- Fig. 2 depicts twenty-five (25) analogues of [carbonyl- n C ⁇ DAAl 106 which have been selected as target molecules from where compounds will be selected according to their affinity and specificity for PBR. Autoradiography and organ distribution using frozen tissues and rats are and have been used as a searching technique for the selection of these compounds. The selected compounds will be used for further biological experiments.
- Fig. 3 shows nine (9) precursor amines used in the synthesis of [ 11 C] DAA analogues.
- a ligand for peripheral type benzodiazepine receptor DAAl 106 and analogues were labeled with 11 C using [ 11 C] carbon monoxide in a palladium mediated carbonylation reaction.
- the reaction was performed in one step in a home made completely automated micro autoclave device.
- the l ⁇ -labeled products were obtained with 15-45% decay-corrected radiochemical yields.
- the synthetic routes for the preparation of precursor amines and reference compounds were also developed.
- the compound N-(2,5-dimethoxybenzyl)-N-(5-fluoro-2-phenoxyphenyl) acetamide or DAAl 106 is a potent and selective ligand for peripheral benzodiazepine receptors (PBR).
- PBR peripheral benzodiazepine receptors
- the PBR is an 18 kDa protein and found in outer mitochondrial membrane in almost all patient tissues and is abundant in steroid-producing cells. These receptors are also found on glial cells of central and peripheral nervous systems and its density increases with the inflammatory reaction of the nervous tissue.
- the ligands for this receptor in combination with PET might be used as markers for neuroinflamation since the inflammation increases the concentration of the receptors for these ligands.
- Fig. 1 Three different PBR ligands such as Ro5-4864, PKl 1195 and DAAl 106 (Fig. 1) have so far been labeled with 11 C and used in PET studies, and in all cases a methylation method for [ 11 C] methyl iodide was used for labeling syntheses.
- the present invention contains the development of a carbonylati ⁇ n method for carbon-isotope labeling of DAAl 106 and making a library of analogues of this compound for finding PET tracers for the study of the function of PBR in neuroinflamation within a patient.
- a useful method for ⁇ C-labeling of DAAl 106 using [ 11 C] carbon monoxide and a micro autoclave technique has been developed and a small library of 25 compounds (Fig 2) have been selected as target molecules from where the most useful compounds will be selected according to their affinity and specificity for PBR. Autoradiography and organ distribution using frozen tissues and rats were used for the searching technique for selection of useful compounds. The selected compounds will be used for further biological experiments.
- the aforementioned micro auto clave technique is a 200 ⁇ L volume autoclave that is connected to a carbon-isotope monoxide system through a five points valve.
- the valve is also connected to a High Performance Liquid Chromotography (HPLC) pump, a product outlet capillary, reagent injection loop and a waste outlet capillary.
- HPLC High Performance Liquid Chromotography
- the autoclave is first charged with carbon-isotope monoxide and then the reagent is loaded into the loop that was forced through the autoclave using a HPLC pump.
- the carbonylation method of labeling DAAl 106 and its analogues by a carbon-isotope monoxide have suggested a clearly favorable contrast in animals when compared to other selective PBR ligands and methods;
- One advantage with the use of the carbonylatioii method is the development of new analogues for carbon-isotope labeling of DAAl 106 analogues.
- the present invention comprises a method for labeling synthesis of a ligand and its analogues for a peripheral type bezodiazepine receptor by: providing a carbon-isotope using a carbon-isotope monoxide in a palladium mediated carbonylation reaction; introducing a micro autoclave technique into said carbonylation reaction whereby converting the carbon-isotope monoxide to a crude product; flashing the crude product with nitrogen to remove furan residues and adding acetonitile whereby forming a resulting solution; and then injecting the" resulting soultion into a liquid chromatograph.
- the ligand for the peripheral type bezodiazepine receptor is 7V-(2,5- dimethoxybenzyl)-AT-(5-fluoro-2-phenoxyphenyi) acetamide or also know as DAAl 106 and the furan residues comprise tetrahydrof ⁇ ran or similar furans.
- analogues of the ligand for the peripheral type bezodiazepine receptor is represented by any one of the labeled compounds below or a combination thereof:
- carbon-isotope can be 11 C, 13 C, or 14 C.
- the concentration of the carbon-isotope monoxide is about ca 10 "2 M to about ca 10 "6 M.
- the concentration of the carbon-isotope monoxide is preferably about ca 10 "4 M.
- the resulting solution is a purified product and the liquid chromatograph used to evaluate the resulting solution is semi-preparitive.
- Another embodiment of the present invention is a method for labeling synthesis of precursor amines for N-(2,5-dimethoxybenzyl)-iV-(5-fluoro-2- phenoxyphenyl) acetamide analogues, comprising the reaction performed by Scheme (2):
- R2 H, OMe
- R3 H, OMe wherein Rl is OMe, F, or hydrogen; R2 is hydrogen or OMe; and R3 is hydrogen or OMe.
- a further embodiment of the present invention involves a labeling synthesis of precursors for N-(2,5-dimethoxybenzyl)-N-(5-fluoro-2- phenoxyphenyl) acetamide analogues, comprising the reaction performed by Scheme (4):
- R1 OMe or H
- R2 OMe or H
- R3 Ome or H wherein Rl is OMe or hydorgen; R2 is OMe or hydrogen; and R3 is OMe or hydrogen.
- the present invention also defines a method for labeling synthesis of reference compounds forN-(2,5- dimethoxybenzyl)-N-(5-fluoro-2-phenoxyphenyl) acetamide analogues, comprising the reaction performed by Scheme (5):
- the present invention shows a method for labeling synthesis of precursor amines wherein the precursor amines are represented by one or more of the following compounds:
- the present invention also provides a kit for a PET study comprising an effective amount of carbon-isotope labeled compound of fig. (3), and pharmaceutically acceptable salts and solvates thereof.
- the present invention further provides a method of use for a PET study
- the ligand for the peripheral type bezodiazepine receptor is N-(2,5- dimethoxybenzyl)-iV-(5-fluoro-2-phenoxyphenyl) acetamide and wherein the analogues of the ligand for the peripheral type bezodiazepine receptor is represented by any one of the compounds below or a combination thereof:
- the carbon-isotope is 11 C, 13 C, or 14 C, wherein the carbon-isotope is preferably 11 C.
- Still another embodiment of the present invention presents the liquid chromatograph as being semi-preparative.
- Yet another embodiment of the present invention presents a method of use for labeling synthesis of precursor amines foriV-(2,5-dimethoxybenzyl)-iV-(5-fluoro-2- phenoxyphenyl) acetamide analogues, comprising the reaction performed by Scheme
- Rl is OMe, F, or hydrogen
- R2 is hydrogen or OMe
- R3 is hydrogen or OMe
- a further embodiment of the present invention presents a method of use for labeling synthesis of precursors for N-(2,5-dimethoxybenzyl)-N-(5-fluoro-2- phenoxyphenyl) acetamide analogues, comprising the reaction performed by Scheme (3):
- Another embodiment of the present invention depicts a method of use for labeling synthesis of precursors for N-(2,5-dimethoxybenzyl)-N-(5-fluoro-2- phenoxyphenyl) acetamide analogues, comprising the reaction performed by Scheme
- R1 OMe or H
- R2 OMe or H
- R3 Ome or H wherein Rl is OMe or hydorgen; R2 is OMe or hydrogen; and R3 is OMe or hydrogen
- Still another embodiment of the present invention depicts a method of use for labeling synthesis of reference compounds forN-(2,5-dimethoxybenzyl)-N-(5-fluoro- 2-phenoxyphenyl) acetamide analogues, comprising the reaction performed by Scheme (5):
- Scheme (5) also depicts the method for labeling synthesis of precursor amines according to a method of use for labeling synthesis of precursor amines for N- (2,5-dimethoxybenzyl)-N-(5-fluoro-2-phenoxyphenyl) acetamide analogues, comprising the reaction performed by Scheme (2):
- Tetrakis (triphenylphosphine) palladium (3.0 mg, 2.7 micromol) was placed in a vial (1 ml), flashed with nitrogen gas in order to make the tetrakis palladium inert inside the vial be removing air and moisture from the vial and anhydrous tetrahydofuran (THF) (200 microL) was added thereafter. The mixture was shaken until the solution was homogeneous and methyl iodide (13.6 mg , 6 microL, 96.4 micromol) was added. The mixture was heated for 5 minutes at 6O 0 C and the solvent was removed by flashing with nitrogen. The residue was dissolved in fresh anhydrous THF (250 microL).
- THF tetrahydofuran
- the micro-autoclave was heated for 5 minutes at 150 0 C.
- the crude product was transferred to a vial (1 niL), THF was removed by flashing with nitrogen and acetonitrile (1 mL) was added.
- the resulting solution was injected in a semi-preparative LC or LC.
- a AMF(40)-MeCN/H 2 O (50:7)(60) solvent was used in the semi preparative LC system.
- a linear gradient to 0:90 within 5 minutes of the LC reading and a flow of 5 niL/min. were achieved.
- a reverse-phase column such as the Jones Chromatography Genesis C 18, 4 micrometers, 250 mm. by 10 mm. was used. Data collection and LC control were performed using a Beckman System Gold chromatography software package.
- a AMF(50)-MeCN/H 2 O (50:7)(50) solvent was used in the analytical LC system with a linear gradient to 0:100 within 6 minutes of the LC reading and a flow of 2 mL/min.
- a reverse-phase column such as the Jones Chromatography Genesis C 18, 4 micrometers, 250 mm. by 4.6 mm. was used. Data collection and LC control were performed using a Beckman System Gold chromatography software package.
- the biologically suitable solution to be injected into the LC was prepared as follows.
- the purified fraction of the product is placed inside an evaporator and the solvent was removed under reduced pressure at 95°C.
- the residue was dissolved in a mixture of sterile propyleneglycol (1 niL), ethanol (99.5%, 1 mL) and a sterile phosphate buffer (4 mL) and was transferred into an injection vial.
- the automated synthesis system, Synthia was used for LC injection and fraction collection transfer of the sample and operation of the evaporator.
- Synthia is a synthetic robot developed at the Uppsala PET center for the handling of radioactive substance and performing some labeling synthesis.
- a description of this device can be found in P. Bjurling, R. Reineck, G. Westerberg, A. D. Gee, J. Sutcliffe, B. Langstr ⁇ m, Proceedings of the VUh workshop on targetry and target chemistry; TRIUMF, Vancouver, Canada, 1995, pp 282-284.
- peripheral type benzodiazepine receptor ligand DAAl 106 and its analogues were labeled with 11 C using [ 11 C] carbon monoxide.
- Palladium mediated carbonylation using tetrakis (triphenylphosphine) palladium, methyl iodide, a concentration of about ca 10 "2 M to about ca 10 "6 M, or a concentration more preferably ca 10 "4 M, of [ 11 C] carbon monoxide and nine different amines (fig. 3) were used in the labeling synthesis (Scheme 1).
- the radiochemical purity was over 97% for all compounds.
- the identification of the labeled products was performed using analytical LC with co-injection of non- radioactive materials.
- the final identification of l ⁇ -labeled compounds will be confirmed by Liquid Chromatography-Mass Spectometry (LC-MS).
- Some of the selected compounds will be labeled with 13 C followed by Nucleur Magnetic Resonance (NMR) analysis for the confirmation of labeling position.
- the precursors for DAAl 106 analogues were prepared by iV-alkylation of 3 different 2-phenoxy anilines (3) with different benzyl halides (4).
- the reaction was performed in presence of CsOH.H 2 O and molecular sieves (MS) in dry DMF.
- the compound 5-fluoro-2-phenoxyaniline (6) used in the JV-alkylation reaction was not commercially available and prepared by reduction of 4-fluoro-2-nitro-l- phenoxybenzene (5).
- the reduction was carried out using hydrazine hydrate in presence of ferric chloride and activated carbon (M. Protiva, J. Jilek, I. Cervena, J. Pomykacek, V. Bartl, A. Dlabak, M. Valchar, J. Metysova, J. Holubak and E. Svatek, Collec. Czech. Chem. Commun. 1986, vol. 51, 2598-2616) and the yield was 96%.
- Scheme 2 Synthesis of precursor amines for DAA analogues.
- Benzyl bromides such as 2,5-Dimethoxybenzyl bromide and 2,3- dimethoxybenzyl bromide used in JV-alkylation reactions were optionally prepared from the corresponding benzyl alcohols by treating with carbon tetrabromide and triphenyl phosphine in dry dichloromethane (Scheme 4). The reaction was performed at ambient temperature for 30 minutes and the yield was 85 to 90%.
- the reaction mixture was filtered to remove the undissolved materials and washed ethyl acetate (50 niL). The filtrate was concentrated under reduced pressure and the residue was taken up in 1 N NaOH (100 ml), and extracted with ethyl acetate (4 x 100 ml). The combined organic layers were washed with brine (2 x 100 ml), dried over anhydrous magnesium sulfate, filtered, and the solvent was removbd under reduced pressure to give the crude product. All of the products were purified by flash column chromatography.
- the reference compounds for two of the labeled target analogues were prepared by treating the amines with acetyl chloride in the presence of pyridine (Scheme 5). These compounds yielded over 90% in both cases.
- the compounds and methods of use thereof described above will allow the clinician to use carbon-isotope labeling of DAAl 106 and make a library of analogues of DAAl 106 for finding useful Positron Emission Tomography tracers for the study of the function of peripheral benzodiazepine receptors in neuroinflamation within a patient.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
A potent and selective ligand for peripheral benzodiazepine receptor (PBR), N-(2,5-dimethoxybenzyl)-N-(5-fluoro-2-phenoxyphenyl)acetamide or DAA1106 and eight structurally related analogues were labelled with 11C at carbonyl position of the molecule using a low concentration of [11C]carbon monoxide and micro autoclave techniques. Palladium mediated carbonylation using tetrakis(triphenylphosphine)palladium, methyl iodide or iodobenzene and different amines was employed in the synthesis. The 11C-labelled products were obtained with 15-45% decay-corrected radiochemical yields. Specific radioactivity was determined for the compound [carbonyl-11C]DAA1106 to investigate the possibility to obtain the high specific radioactivity for the compounds prepared using this method. The obtained specific radioactivity was 121 GBq/µmol, 36 min after a bombardment of 10 µAh. Synthetic routes for the preparation of precursors and reference compounds were also developed. The presented approach is a novel method for the synthesis of [carbonyl-11C]DAA1106 and analogues. Accordingly, the synthetic routes for the preparation of precursor amines and reference compounds are provided. A kit claim and a method of use claim for a PET study comprising an effective amount of carbon-isotope labeled compound and pharmaceutically acceptable salts and solvates thereof are also provided.
Description
Carbon-isotope monoxide labeling of DAA1106 and its analogues to be used as tracers for a peripheral type benzodiazepine binding site
Field of the Invention
The present invention relates to analogues of DAAl 106 and a carbonylation method of labeling DAAl 106 and its analogues by carbon-isotope monoxide in a palladium mediated carbonylation reaction for the study of the function of peripheral benzodiazepine receptors in the neuroinflammation of a patient. The synthetic routes for the preparation of precursor amines and reference compounds were also developed.
Background of the Invention
Positron emission tomography ("PET") is a non-invasive imaging technique based on the detection of positron annihilation radiation and has become a tool of choice for many diagnostic medical applications. Moreover, this technique allows the investigation of biochemical transformations of drugs or other molecules in living systems and thereby offers possibilities to study physiology, molecular biology, energy metabolism, drug-receptor or drug-enzyme interactions etc. and can play an important role in the discovery of new drugs. The micro dosing concept of PET can be a useful strategy for speeding up the drug development process.1
Any investigation using PET requires the target molecules to label with short lived positron emitting radionuclides like 11C, 18F, 76Br, 68Ga etc. Among these, 11C is very important to PET radiochemists because of its half life (t>/2 = 20.4 min) which is almost optimal from the synthetic point of view and also a wide rage of compounds can be labelled with 11C. The 11 C-labelled biologically interesting molecules are used as PET tracer for various biological investigations in vitro and in vivo. The demand for new method for the synthesis of labelled molecules is continuously increasing with increasing use of PET in medical and biomedical research as well as in various clinical applications. Although the methods most commonly used for the synthesis of πC-labelled compounds are S-, O- and iV-methylations using [uC]methyl iodide or [nC]methyl triflate, the application of carbonylation using [uC]carbon monoxide has recently become an increasingly employed l ^-labelling strategy.
During the last two decades carbonylation chemistry using carbon monoxide has developed significantly. The recent development of methods such as palladium- catalyzed carbonylative coupling reactions has provided a mild and efficient tool for the transformation of carbon monoxide into different carbonyl compounds.
Carbonylation reactions using [11C] carbon monoxide have a primary value for
PET -tracer synthesis since biologically active substances often contain carbonyl groups or functionalities that can be derived from a carbonyl group. The syntheses are tolerant to most functional groups, which means that complex building blocks can be assembled in the carbonylation step to yield the target compound. This is particularly valuable in PET-tracer synthesis where the unlabeled substrates should be
combined with the labeled precursor as late as possible in the reaction sequence, in order to decrease synthesis-time and thus optimize the uncorrected radiochemical yield.
When compounds are labeled with 11C, it is usually important to maximize specific radioactivity. In order to achieve this, the isotopic dilution and the synthesis time must be minimized. Isotopic dilution from atmospheric carbon dioxide may be
substantial when [11C] carbon dioxide is used in a labeling reaction. Due to the low
reactivity and atmospheric concentration of carbon monoxide (0.1 ppm vs. 3.4 x I O4
ppm for CO2), this problem is reduced with reactions using [11C] carbon monoxide.
The synthesis of [11C] carbon monoxide from [11C] carbon dioxide using a heated column containing reducing agents such as zinc, charcoal or molybdenum has
been described previously in several publications. Although [11C] carbon monoxide
was one of the first πC-labeled compounds to be applied in tracer experiments in
! human, it has until recently not found any practical use in the production of PET- tracers. One reason for this is the low solubility and relative slow reaction rate of
[11C] carbon monoxide which causes low trapping efficiency in reaction media. The
general procedure using precursors such as [11C] methyl iodide, [11C] hydrogen cyanide or f11C] carbon dioxide is to transfer the radioactivity in a gas-phase, and trap the radioactivity by leading the gas stream through a reaction medium. Until recently this has been the only accessible procedure to handle [11C] carbon monoxide in labeling synthesis. With this approach, the main part of the labeling syntheses with
[11C] carbon monoxide can be expected to give a very low yield or fail completely.
There are only a few examples of practically valuable 1 !C-labeling syntheses using high pressure techniques (> 300 bar). In principal, high pressures can be utilized for increasing reaction rates and minimizing the amounts of reagents. One problem with this approach is how to confine the labeled precursor in a small high- pressure reactor. Another problem is the construction of the reactor. If a common column type of reactor is used (i.e. a cylinder with tubing attached to each end), the gas-phase will actually become efficiently excluded from the liquid phase at pressurization. The reason is that the gas-phase, in contracted form, will escape into the attached tubing and away from the bulk amount of the liquid reagent.
The cold-trap technique is widely used in the handling of πC-labeled precursors, particularly in the case of [11C] carbon dioxide. The procedure has, however, only been performed in one single step and the labeled compound was always released in a continuous gas-stream simultaneous with the heating of the cold- trap. Furthermore, the volume of the material used to trap the labeled compound has been relative large in relation to the system to which the labeled compound has been transferred. Thus, the option of using this technique for radical concentration of the labeled compound and miniaturization of synthesis systems has not been explored. This is especially noteworthy in view of the fact that the amount of a l ^-labeled compound usually is in the range of 20-60 nmol.
Recent technical development for the production and use of [l C] carbon monoxide has made this compound useful in labeling synthesis. WO 02/102711
describes a system and a method for the production and use of a carbon-isotope monoxide enriched gas-mixture from an initial carbon-isotope dioxide gas mixture. [ C] carbon monoxide may be obtained in high radiochemical yield from cyclotron produced [11C] carbon dioxide and can be used to yield target compounds with high specific radioactivity. This reactor overcomes the difficulties listed above and is useful in synthesis of l ^-labeled compounds using [11C] carbon monoxide in palladium or selenium mediated reaction. With such method, a broad array of carbonyl compounds can be labeled (Kilhlberg, T.; Langstrom, B. J., Org. Chem., vol. 64, 1999, 9201-9205; Kihlberg, T., Karimi, F., Langstrom, B., J. Org. Chem., vol. 67, 2002, 3687-3692). Additionally, [13C] and [14C]-labeled compounds using [13C] and [14C] carbon monoxide in palladium or selenium mediated reactions are presented as part of this carbon monoxide carbon monoxide carbon monoxide
In the present invention, carbonylation methods for labeling [11C ] compounds was studied in order to obtain the best tracer for visualization and characterization of a peripheral type benzodiazepine binding site, peripheral benzodiazepine receptors (PBR). A PBR is an 18 IeDa protein that is found in outer mitochondrial membranes in almost all tissues and is abundant in steroid-producing cells. PBRs are also found on glial cells of central and peripheral nervous systems and its density increases with the inflammatory reaction of the nervous tissue. J. Maeda et. al, SYNAPSE, 2004, vol. 52, 283-291.
Furthermore, PBR is expressed in most organs and its expression is reported to be increased in activated microglia in the brain. PBR ligands such as [11C]PKl 1195
have been widely used for the in vivo imaging of PBRs, Id. The prototype PBR ligands Ro5-4864 and the isoquinoline carboxamide, PKl 1195 have been widely used to determine the cellular expression and function of PBR in various tissues wherein a ligand is defined as a group, ion, or molecule coordinated to a central atom or molecule in a complex.
Accordingly, there is a need for creating new synthesis methods, expanding such methods to generate new compounds for the labeling of DAAl 106 and making a library of analogues of these compounds for finding PET tracers for the study of the function of peripheral benzodiazepine receptor (PBR) in neuroinflammation within a patient wherein PBR is a key element of the steroidogenic pathway in peripheral tissues.
The term "analogue" used throughout this invention is defined as a chemical compound that is structurally similar to DAAl 106 but differs in composition i.e. elements, functional groups.
Discussion or citation of a reference herein shall not be construed as an admission that such reference is prior art to the present invention.
Summary of the Invention
In view of the needs of the prior art, the present invention provides a method that relates to a carbonylation method for the labeling of DAAl 106 and making a library of analogues of this compound for finding Positron Emission Tomography (PET) tracers for the study of the function of peripheral benzodiazepine receptors (PBR) in the neuroinflammation of a patient.
Additionally, the present invention depicts a method for labeling synthesis of a ligand and its analogues for a peripheral type bezodiazepine receptor, comprising: providing a carbon-isotope using a carbon-isotope monoxide in a palladium mediated carbonylation reaction; introducing a micro autoclave technique into said carbonylation reaction whereby converting the carbon-isotope monoxide to a crude product; flashing the crude product with nitrogen to remove furan residues and adding acetonitile whereby forming a resulting solution; and injecting the resulting soultion into a liquid chromatograph.
In a further embodiment, a method for labeling synthesis of precursor amines for iV-(2,5-dimethoxybenzyl)-iV-(5-fluoro-2-phenoxyphenyl) acetamide analogues is claimed as Scheme (2).
R1 = OMe, Cl, H
X = F, Cl, H Y = Br, Cl R2 = H, OMe R3 = H, OMe wherein Rl is OMe, F, or hydrogen; R2 is hydrogen or OMe; and R3 is hydrogen or OMe.
Scheme (2)
In yet another embodiment of the present invention presents another method for labeling synthesis of precursors forN-(2,5-dimethoxybenzyl)-iV-(5-fluoro-2- phenoxyphenyl) acetamide analogues, which comprises the reaction performed by Scheme (3):
Scheme (3)
In another embodiment, the present invention shows a method for labeling synthesis of precursors for N-(2,5-dimethoxybenzyl)-N-(5-fluoro-2-phenoxyphenyl) acetamide analogues, comprising the reaction performed by Scheme (4):
R1 = OMe or H R2 = OMe or H R3 = Ome or H wherein Rl is OMe or hydorgen; R2 is OMe or hydrogen; and R3 is OMe or hydrogen.
Scheme (4)
Additionally, another embodiment shows a method for labeling synthesis of reference compounds for iV-(2,5-dimethoxybenzyl)-iV-(5-fluoro-2-phenoxyphenyl) acetamide analogues, comprising the reaction performed by Scheme (5):
10 11 X = F, Cl wherein X is F or Cl
Scheme (5)
Brief Description of Figures
Fig. 1 shows the different structures and composition make up of three peripheral benzodiazepine receptor (PBR) ligands, Ro5-4864, PKl 1195, and DAAl 106 that have been labeled with [11C].
Fig. 2 depicts twenty-five (25) analogues of [carbonyl-nC\ DAAl 106 which have been selected as target molecules from where compounds will be selected according to their affinity and specificity for PBR. Autoradiography and organ distribution using frozen tissues and rats are and have been used as a searching
technique for the selection of these compounds. The selected compounds will be used for further biological experiments.
Fig. 3 shows nine (9) precursor amines used in the synthesis of [11C] DAA analogues.
Detailed Description of the Invention
A ligand for peripheral type benzodiazepine receptor DAAl 106 and analogues were labeled with 11C using [11C] carbon monoxide in a palladium mediated carbonylation reaction. The reaction was performed in one step in a home made completely automated micro autoclave device. The l ^-labeled products were obtained with 15-45% decay-corrected radiochemical yields. The synthetic routes for the preparation of precursor amines and reference compounds were also developed.
The compound N-(2,5-dimethoxybenzyl)-N-(5-fluoro-2-phenoxyphenyl) acetamide or DAAl 106 is a potent and selective ligand for peripheral benzodiazepine receptors (PBR). The PBR is an 18 kDa protein and found in outer mitochondrial membrane in almost all patient tissues and is abundant in steroid-producing cells. These receptors are also found on glial cells of central and peripheral nervous systems and its density increases with the inflammatory reaction of the nervous tissue. The ligands for this receptor in combination with PET might be used as markers for neuroinflamation since the inflammation increases the concentration of the receptors for these ligands. Three different PBR ligands such as Ro5-4864, PKl 1195 and DAAl 106 (Fig. 1) have so far been labeled with 11C and used in PET studies, and in
all cases a methylation method for [11C] methyl iodide was used for labeling syntheses. The present invention contains the development of a carbonylatiόn method for carbon-isotope labeling of DAAl 106 and making a library of analogues of this compound for finding PET tracers for the study of the function of PBR in neuroinflamation within a patient.
A useful method for πC-labeling of DAAl 106 using [11C] carbon monoxide and a micro autoclave technique has been developed and a small library of 25 compounds (Fig 2) have been selected as target molecules from where the most useful compounds will be selected according to their affinity and specificity for PBR. Autoradiography and organ distribution using frozen tissues and rats were used for the searching technique for selection of useful compounds. The selected compounds will be used for further biological experiments.
The aforementioned micro auto clave technique is a 200 μL volume autoclave that is connected to a carbon-isotope monoxide system through a five points valve. The valve is also connected to a High Performance Liquid Chromotography (HPLC) pump, a product outlet capillary, reagent injection loop and a waste outlet capillary. The autoclave is first charged with carbon-isotope monoxide and then the reagent is loaded into the loop that was forced through the autoclave using a HPLC pump.
Furthermore, the carbonylation method of labeling DAAl 106 and its analogues by a carbon-isotope monoxide have suggested a clearly favorable contrast in animals when compared to other selective PBR ligands and methods; One
advantage with the use of the carbonylatioii method is the development of new analogues for carbon-isotope labeling of DAAl 106 analogues. There are several additional advantages with using the present method over previous methods. Since labeled metabolites might be a confounding factor, the option of labeling DAAl 106 in other positions may be valuable and, accordingly, the carbonyl labeling will allow the formation of analogues of the compound. For example, by using [11C] carbon monoxide for labeling [11C] DAAl 106 as opposed to labeling [11C] DAAl 006 with [11C] methyl iodide may enable a clinician to see a greater contrast between the binding and non-binding site expressing areas of PBR.
Below a detailed description is given of a method for labeling DAAl 106 and making a library of analogues of this compound for finding PET tracers for the study of the function of PBR in neoroinfmammation.
In one embodiment of the present invention comprises a method for labeling synthesis of a ligand and its analogues for a peripheral type bezodiazepine receptor by: providing a carbon-isotope using a carbon-isotope monoxide in a palladium mediated carbonylation reaction; introducing a micro autoclave technique into said carbonylation reaction whereby converting the carbon-isotope monoxide to a crude product; flashing the crude product with nitrogen to remove furan residues and adding acetonitile whereby forming a resulting solution; and then injecting the" resulting soultion into a liquid chromatograph.
Wherein, the ligand for the peripheral type bezodiazepine receptor is 7V-(2,5- dimethoxybenzyl)-AT-(5-fluoro-2-phenoxyphenyi) acetamide or also know as DAAl 106 and the furan residues comprise tetrahydrofαran or similar furans.
In a further embodiment, the analogues of the ligand for the peripheral type bezodiazepine receptor is represented by any one of the labeled compounds below or a combination thereof:
DORP DORQ DORR
DORV DORW DORX
DORY
An additional embodiment of the present invention is that carbon-isotope can be 11C, 13C, or 14C.
Another embodiment of the present invention is where the palladium mediated carbonylation reaction is represented by Scheme (1):
Scheme (1)
wherein the concentration of the carbon-isotope monoxide is about ca 10"2 M to about ca 10"6 M. The concentration of the carbon-isotope monoxide is preferably about ca 10"4 M. Additionally, the resulting solution is a purified
product and the liquid chromatograph used to evaluate the resulting solution is semi-preparitive.
Another embodiment of the present invention is a method for labeling synthesis of precursor amines for N-(2,5-dimethoxybenzyl)-iV-(5-fluoro-2- phenoxyphenyl) acetamide analogues, comprising the reaction performed by Scheme (2):
4 1
R1 = OMe, Cl, H
X = F, Cl, H Y = Br, Cl R2 = H, OMe R3 = H, OMe wherein Rl is OMe, F, or hydrogen; R2 is hydrogen or OMe; and R3 is hydrogen or OMe.
Scheme (2)
In yet another embodiment of the present invention depicts a labeling synthesis of precursors for N-(2,5-dimethoxybenzyl)-N-(5-fluoro-2- phenoxyphenyl) acetamide analogues, comprising the reaction performed by Scheme (3):
Scheme (3)
A further embodiment of the present invention involves a labeling synthesis of precursors for N-(2,5-dimethoxybenzyl)-N-(5-fluoro-2- phenoxyphenyl) acetamide analogues, comprising the reaction performed by Scheme (4):
R1 = OMe or H R2 = OMe or H R3 = Ome or H wherein Rl is OMe or hydorgen; R2 is OMe or hydrogen; and R3 is OMe or hydrogen.
Scheme (4)
Additionally, in a preferred embodiment, the present invention also defines a method for labeling synthesis of reference compounds forN-(2,5- dimethoxybenzyl)-N-(5-fluoro-2-phenoxyphenyl) acetamide analogues, comprising the reaction performed by Scheme (5):
Scheme (5)
Additionally, in another embodiment, the present invention shows a method for labeling synthesis of precursor amines wherein the precursor amines are represented by one or more of the following compounds:
The present invention also provides a kit for a PET study comprising an effective amount of carbon-isotope labeled compound of fig. (3), and pharmaceutically acceptable salts and solvates thereof.
The present invention further provides a method of use for a PET study
comprising an effective amount of carbon-isotope labeled compound of fig. (3), and
pharmaceutically acceptable salts and solvates thereof, wherein the compound can be
one or more of the following structures:
DORM DORN DORO
DORP DORQ DORR
DORS DORT DORU
DORY
wherein * is the Labeling position.
A further embodiment of the present invention is wherein the method of use for labeling synthesis of a ligand and its analogues for a peripheral type bezodiazepine receptor is used according to the follow method:
(i) providing a carbon-isotope using a carbon-isotope monoxide in a palladium mediated carbonylation reaction; (ii) introducing a micro autoclave technique into said carbonylation reaction whereby converting the carbon- isotope monoxide to a crude product; (iii) flashing the crude product with nitrogen to remove furan residues and adding acetonitile whereby forming a resulting solution; and
(iv) injecting the resulting soultion into a liquid chromatograph.
wherein the ligand for the peripheral type bezodiazepine receptor is N-(2,5- dimethoxybenzyl)-iV-(5-fluoro-2-phenoxyphenyl) acetamide and wherein the analogues of the ligand for the peripheral type bezodiazepine receptor is represented by any one of the compounds below or a combination thereof:
DORJ DORL
DORK
DORP DORQ DORR
DORV DORW DORX
DORY wherein * is the Labeling position.
Furthermore, the carbon-isotope is 11C, 13C, or 14C, wherein the carbon-isotope is preferably 11C.
Yet another embodiment of the present invention presents that the palladium mediated carbonylation reaction is represented by scheme (1):
Scheme (1) wherein the concentration of the carbon-isotope monoxide is about ca 10 v"z2 M- to about ca 10"6 M.
A further embodiment of the present invention presents a method of use wherein the concentration of the carbon isotope monoxide is about ca 10~4 M. and wherein the resulting solution is a purified product.
Still another embodiment of the present invention presents the liquid chromatograph as being semi-preparative.
Yet another embodiment of the present invention presents a method of use for labeling synthesis of precursor amines foriV-(2,5-dimethoxybenzyl)-iV-(5-fluoro-2- phenoxyphenyl) acetamide analogues, comprising the reaction performed by Scheme
(2):
R1 = OMe, Cl, H
X = F, Cl, H Y = Br, Cl R2 = H, OMe R3 = H, OMe
wherein Rl is OMe, F, or hydrogen; R2 is hydrogen or OMe; and R3 is hydrogen or OMe
Scheme (2).
A further embodiment of the present invention presents a method of use for labeling synthesis of precursors for N-(2,5-dimethoxybenzyl)-N-(5-fluoro-2- phenoxyphenyl) acetamide analogues, comprising the reaction performed by Scheme (3):
Scheme (3).
Another embodiment of the present invention depicts a method of use for labeling synthesis of precursors for N-(2,5-dimethoxybenzyl)-N-(5-fluoro-2- phenoxyphenyl) acetamide analogues, comprising the reaction performed by Scheme
R1 = OMe or H R2 = OMe or H R3 = Ome or H wherein Rl is OMe or hydorgen; R2 is OMe or hydrogen; and R3 is OMe or hydrogen
Scheme (4).
Still another embodiment of the present invention depicts a method of use for labeling synthesis of reference compounds forN-(2,5-dimethoxybenzyl)-N-(5-fluoro- 2-phenoxyphenyl) acetamide analogues, comprising the reaction performed by Scheme (5):
10 11
X = F, Cl wherein X is F or Cl
Scheme (5).
The present invention also depicts the method for labeling synthesis of precursor amines according to a method of use for labeling synthesis of precursor amines for N- (2,5-dimethoxybenzyl)-N-(5-fluoro-2-phenoxyphenyl) acetamide analogues, comprising the reaction performed by Scheme (2):
4 1
R1 = OMe, Cl, H
X = F, Cl, H Y = Br, Cl R2 =, H, OMe R3 = H, OMe
Scheme (2) wherein Rl is OMe, F, or hydrogen; R2 is hydrogen or OMe; and R3 is hydrogen or OMe, and further wherein the precursor amines are represented by one or more of the following compounds:
8
Examples
The invention is further described in the following examples which are in no way intended to limit the scope of the invention.
General method for preparing "C-Iabeling synthesis
Tetrakis (triphenylphosphine) palladium (3.0 mg, 2.7 micromol) was placed in a vial (1 ml), flashed with nitrogen gas in order to make the tetrakis palladium inert inside the vial be removing air and moisture from the vial and anhydrous tetrahydofuran (THF) (200 microL) was added thereafter. The mixture was shaken until the solution was homogeneous and methyl iodide (13.6 mg , 6 microL, 96.4 micromol) was added. The mixture was heated for 5 minutes at 6O0C and the solvent was removed by flashing with nitrogen. The residue was dissolved in fresh anhydrous THF (250 microL).
An amine (as shown in fig. 3) (14.1 micromol) was placed in another vial (1 niL), flashed with nitrogen and dissolved in anhydrous THF (200 microL). The solution was treated with BuLi (10 microL of 1.6 M solution, 16.0 micromol), heated for 5 minutes at 60°C (no heating was needed for DORA) and the solvent was removed by flashing with nitrogen. The residue was dissolved in fresh anhydrous THF (250 microL).
The two reagent solutions were mixed together, filtered and injected into the loop of a Liquid Chromatography (LC) from where the mixture was transferred with pressure (35 Mpa) into the micro autoclave (200 microl), pre-charged with [11C] carbon monoxide in helium. The micro-autoclave was heated for 5 minutes at 1500C. The crude product was transferred to a vial (1 niL), THF was removed by flashing with nitrogen and acetonitrile (1 mL) was added. The resulting solution was injected in a semi-preparative LC or LC.
A AMF(40)-MeCN/H2O (50:7)(60) solvent was used in the semi preparative LC system. A linear gradient to 0:90 within 5 minutes of the LC reading and a flow of 5 niL/min. were achieved. A reverse-phase column such as the Jones Chromatography Genesis C 18, 4 micrometers, 250 mm. by 10 mm. was used. Data collection and LC control were performed using a Beckman System Gold chromatography software package.
A AMF(50)-MeCN/H2O (50:7)(50) solvent was used in the analytical LC system with a linear gradient to 0:100 within 6 minutes of the LC reading and a flow of 2 mL/min. A reverse-phase column such as the Jones Chromatography Genesis C 18, 4 micrometers, 250 mm. by 4.6 mm. was used. Data collection and LC control were performed using a Beckman System Gold chromatography software package.
The biologically suitable solution to be injected into the LC was prepared as follows. The purified fraction of the product is placed inside an evaporator and the solvent was removed under reduced pressure at 95°C. The residue was dissolved in a
mixture of sterile propyleneglycol (1 niL), ethanol (99.5%, 1 mL) and a sterile phosphate buffer (4 mL) and was transferred into an injection vial. The automated synthesis system, Synthia, was used for LC injection and fraction collection transfer of the sample and operation of the evaporator.
Synthia is a synthetic robot developed at the Uppsala PET center for the handling of radioactive substance and performing some labeling synthesis. A description of this device can be found in P. Bjurling, R. Reineck, G. Westerberg, A. D. Gee, J. Sutcliffe, B. Langstrδm, Proceedings of the VUh workshop on targetry and target chemistry; TRIUMF, Vancouver, Canada, 1995, pp 282-284.
Example 1 - Experiemental Studies
I. Labeling synthesis of DAA1106 and analogues
The peripheral type benzodiazepine receptor ligand DAAl 106 and its analogues were labeled with 11C using [11C] carbon monoxide. Palladium mediated carbonylation using tetrakis (triphenylphosphine) palladium, methyl iodide, a concentration of about ca 10"2 M to about ca 10"6 M, or a concentration more preferably ca 10"4 M, of [11C] carbon monoxide and nine different amines (fig. 3) were used in the labeling synthesis (Scheme 1).
Scheme 1. Synthesis of [carbonyl- 11/ C]DAA analogues.
The reaction was performed in a micro autoclave of 200 μL. The conversion of [ rl l C] carbon monoxide to crude products (trapping efficiency) was over 95% for all cases (Table 1) and the decay corrected radiochemical yields of LC-purified products, calculated from [11C] carbon monoxide, were 10 to 40% (Table 1).
Table 1. Trapping efficiency and radiochemical yields for the * ^-labelled DAAl 106 and analogues shown in Fig 2.
TE = Trapping Efficiency, decay-corrected, the fraction of radioactivity left in the crude product after purge with nitrogen, 8RCY= radiochemical yield; decay-corrected and determined by analytical LC on the basis of radioactivity in the crude product before nitrogen purging and the purity of crude product, the value is the mean value of at least 3 experiments. Values in parenthesis are the isolated yields.
The radiochemical purity was over 97% for all compounds. The identification of the labeled products was performed using analytical LC with co-injection of non- radioactive materials. The final identification of l ^-labeled compounds will be confirmed by Liquid Chromatography-Mass Spectometry (LC-MS). Some of the selected compounds will be labeled with 13C followed by Nucleur Magnetic Resonance (NMR) analysis for the confirmation of labeling position.
Compound DAAl 106 was previously labeled with 11C using [11C] methyl iodide and in that strategy only DAAl 106 could be labeled with 11C. No other 11C- labeled analogues of that compound could be labeled using [11C] methyl iodide. On the other hand, carbonylation using [11C] carbon monoxide gave a possibility to prepare a series of x ^-labeled analogues of DAAl 106 and 25 compounds have been selected as the initial step of this study.
In initial experiments, said reaction was performed with non activated amines i.e. amines without any additional base and the reaction worked very poorly. The radiochemical yield was only 5%. The activation of amines is usually essential for improving the radiochemical yields of ' ^-labeled amides prepared by carbonylation reactions using [11C] carbon monoxide. Different bases for the activation of amines
were used. Furthermore, the activation of amines with BuLi gave considerable improvement to the radiochemical yield. Wherein the radioactive yield of activated amines was 40% when the reaction was performed after activation of amine using BuLi, i.e. the improved radiochemical yield difference between the activated and non activated amines was 35%.
The procedure described above can be used for 13C and 14C-labeling of DAAl 006 and its analogues by [13C] and [14C] monoxide in a palladium mediated carbonylation reaction.
II. Synthesis of the precursors of the DAA analogues
The precursors for DAAl 106 analogues were prepared by iV-alkylation of 3 different 2-phenoxy anilines (3) with different benzyl halides (4). The reaction was performed in presence of CsOH.H2O and molecular sieves (MS) in dry DMF.
X=F, R1 =R3=OMe, R2=H (1a); X=F, RI =CI, R2=R3=H (1b); X=H, R1 =R3=OMe, R2=H (1c); X=H, R1=H, R2=R3=OMe (1d); X=H, RI=CI, R2=R3=H (1e); X=H, R1=R2=OMe, R3=H (1f); X=CI, R1=H, R2=R3=OMe (1g); X=CI, R1=R3=OMe, R2=H (1 h).
The yields for the target amines varied from 65 to 90% (Table 2). The yields were lower, 45 and 40% for compounds Id and Ig respectively (entries 4 and 7 in Table 2) when benzyl chloride instead of benzyl bromide was used as substrate, since chloride is worse leaving group than bromide in substitution reactions. Only one (Ia) of eight prepared amines (Ia-Ih) was known previously. All other seven amines (Ib- Ih) are novel compounds, The problem of over alkylation, which is the main problem in N-alkylation reactions, could be avoided using this method. Almost no di- or tri- alkylated product was formed.
Table 2. Yields of the precursor amines (Ia-Ih).
41
The compound 5-fluoro-2-phenoxyaniline (6) used in the JV-alkylation reaction was not commercially available and prepared by reduction of 4-fluoro-2-nitro-l- phenoxybenzene (5). The reduction was carried out using hydrazine hydrate in presence of ferric chloride and activated carbon (M. Protiva, J. Jilek, I. Cervena, J. Pomykacek, V. Bartl, A. Dlabak, M. Valchar, J. Metysova, J. Holubak and E. Svatek, Collec. Czech. Chem. Commun. 1986, vol. 51, 2598-2616) and the yield was 96%. Scheme 2. Synthesis of precursor amines for DAA analogues.
One of three phenoxy anilines i.e. 5-fluoro-2-phenoxyaniline (7) used in the iV-alkylation reaction was prepared in three steps starting with 2,5-difluoro- nitrobenzene (5) (Scheme 3).
Scheme 3. Synthesis of 5-fluoro-2-phenoxyaniline.
The nucleophilic aromatic substitution of 2,5-difluoro-nitrobenzene with phenoxide ion gave 5-fluoro-2-phenoxy-nitrobenzene (6). The yield for this step was 97%. The nitrobenzene 5 was reduced to aniline 7 using hydrazine hydrate in presence of ferric chloride and activated coal. The yield for this step was 96%.
Benzyl bromides such as 2,5-Dimethoxybenzyl bromide and 2,3- dimethoxybenzyl bromide used in JV-alkylation reactions were optionally prepared from the corresponding benzyl alcohols by treating with carbon tetrabromide and triphenyl phosphine in dry dichloromethane (Scheme 4). The reaction was performed at ambient temperature for 30 minutes and the yield was 85 to 90%.
R1 = OMe or H R2 = OMe or H R3 = Ome or H
Scheme 4. Synthesis of benzyl bromides from benzyl alcohols.
The procedure described above can be used for 13C and 14C-labeling of
DAA1006 and its analogues by [13C] and [14C] monoxide in a palladium mediated carbonylation reaction.
Synthesis of precursor amines Ia-Ih. The procedure is exemplified by the preparation of 2V-(2,5- dimethoxybenzyl)-iV-(5- fluoro-2-phenoxyphenyl)amine (Ia).
A suspension of activated powdered 4 A molecular sieves (5.00 g) and cesium hydroxide monohydrate (3.12 g, 18.93 mmol) in anhydrous DMF (100 mL) was stirred vigorously for 10 min at ambient temperature. A solution of 5-fluoro-2- phenoxyaniline (3.30 g, 16.25 mmol) in anhydrous DMF (10 mL) was added slowly and the mixture was stirred for an additional 30 min. at the same temperature. Finally a solution of 2-(bromomethyl)-l,4- dimethoxybenzene (3.61 g, 16.24 mmol) in dry DMF (10 mL) was added to the white suspension, and the reaction was allowed to proceed at 700C for 4 h. The reaction mixture was filtered to remove the undissolved
materials and washed ethyl acetate (50 niL). The filtrate was concentrated under reduced pressure and the residue was taken up in 1 N NaOH (100 ml), and extracted with ethyl acetate (4 x 100 ml). The combined organic layers were washed with brine (2 x 100 ml), dried over anhydrous magnesium sulfate, filtered, and the solvent was removbd under reduced pressure to give the crude product. All of the products were purified by flash column chromatography. Two times flashing, first using pentane/dichloromethane/di ethyl ether (8:1 :1 v/v) and then pentane/diethyl ether (8:2 v/v) as the eluents were needed to get the pure product.
III. Synthesis of reference compounds for DAA analogues
The reference compounds for two of the labeled target analogues (fig. 2) were prepared by treating the amines with acetyl chloride in the presence of pyridine (Scheme 5). These compounds yielded over 90% in both cases.
10 11 X = F1 CI
Scheme 5. Synthesis of reference compounds for DAA analogues.
The procedure described above can be used for 13C and 14C-labeling of DAAl 006 and its analogues by [13C] and [14C] monoxide in a palladium mediated carbonylation reaction.
IV. Results
The compounds and methods of use thereof described above will allow the clinician to use carbon-isotope labeling of DAAl 106 and make a library of analogues of DAAl 106 for finding useful Positron Emission Tomography tracers for the study of the function of peripheral benzodiazepine receptors in neuroinflamation within a patient.
Specific Embodiments, Citation of References
The present invention is not to be limited in scope by specific embodiments described herein. Indeed, various modifications of the inventions in addition to those described herein will become apparent to those skilled in the art from the foregoing description and accompanying figures. Such modifications are intended to fall within the scope of the appended claims.
Various publications and patent applications are cited herein, the disclosures of which are incorporated by reference in their entireties.
Claims
1. A method for labeling synthesis of a ligand and its analogues for a peripheral type bezodiazepine receptor, comprising:
(v) providing a carbon-isotope using a carbon-isotope monoxide in a palladium mediated carbonylation reaction;
(vi) introducing a micro autoclave technique into said carbonylation reaction whereby converting the carbon- isotope monoxide to a crude product;
(vii) flashing the crude product with nitrogen to remove furan residues and adding acetonitile whereby forming a resulting solution; and (viii) injecting the resulting soultion into a liquid chromatograph.
2. The method according to claim 1, wherein the ligand for the peripheral type bezodiazepine receptor is N-(2,5-dimethoxybenzyl)-iV-(5-fluoro-2- phenoxyphenyl) acetamide.
3. The method according to claim 1, wherein the analogues of the ligand for the peripheral type bezodiazepine receptor is represented by any one of the compounds below or a combination thereof:
DORP DORQ DORR
DORY wherein * is the Labeling position.
4. The method according to claim 1, wherein the carbon-isotope is 11/ C-M, 13k C, or 14C.
5. The method according to claim 1, wherein the carbon-isotope is 11/ C.
6. The method according to claim 1, wherein the palladium mediated carbonylation reaction is represented by scheme (1):
Scheme (1) wherein the concentration of the carbon-isotope monoxide is about ca 10" M to about ca 10"6 M.
7. The method according to claim 6, wherein the concentration of the carbon isotope monoxide is about ca 10'4 M.
8. The method according to claim 1, wherein the resulting solution is a purified product.
9. The method according to claim 1, wherein the liquid chromatograph is semi-preparitive.
10. A method for labeling synthesis of precursor amines for N-(2,5- dimethoxybenzyl)-N-(5-fluoro-2-phenoxyphenyl) acetamide analogues, comprising the reaction performed by Scheme (2):
1
R1 = OMe, Cl, H
X = F, Cl, H Y = Br, Cl R2 = H, OMe R3 = H, OMe wherein Rl is OMe, F, or hydrogen; R2 is hydrogen or OMe; and R3 is hydrogen or OMe Scheme (2).
11. A method for labeling synthesis of precursors for N-(2,5- dimethoxybenzyl)-N-(5-fluoro-2-phenoxyphenyl) acetamide analogues, comprising the reaction performed by Scheme (3):
Scheme (3).
12. A method for labeling synthesis of precursors for N-(2,5- dimemoxybenzyl)-iV-(5-fluoro-2-phenoxyphenyl) acetamide analogues, comprising the reaction performed by Scheme (4):
8 9
R1 = OMe or H R2 = OMe or H R3 = Ome or H wherein Rl is OMe or hydorgen; R2 is OMe or hydrogen; and R3 is OMe or hydrogen
Scheme (4).
13. A method for labeling synthesis of reference compounds for N-(2,5- dimethoxybenzyl)-iV-(5-fluoro-2-phenoxyphenyl) acetamide analogues, comprising the reaction performed by Scheme (5):
10 11
X = F1 CI wherein X is F or Cl
Scheme (5).
14. The method for labeling synthesis of precursor amines according to claim 10, wherein the precursor amines are represented by one or more of the following compounds:
15. A kit for a PET study comprising an effective amount of carbon-isotope labeled compound of fig. (3), and pharmaceutically acceptable salts and solvates thereof, wherein the compound can be one or more of the referenced structures: •
DORD DORE DORF
DORJ
DORK DORL
DORP DORQ DORR
DORY wherein * is the Labeling position.
16. A method of use for a PET study comprising an effective amount of carbon-
isotope labeled compound of fig. (3), and pharmaceutically acceptable salts and
solvates thereof, wherein the compound can be one or more of the referenced
structures in claim 15.
17. The method of use for labeling synthesis of a ligand and its analogues for a
peripheral type bezodiazepine receptor according to claim 1.
18. The method of use according to claim 17, wherein the ligand for the peripheral type bezodiazepine receptor is N-(2,5-dimethoxybenzyl)-N-(5-fluoro-2- phenoxyphenyl) acetamide.
19. The method of use according to claim 17, wherein the analogues of the ligand for the peripheral type bezodiazepine receptor is represented by any one of the compounds below or a combination thereof:
DORD DORE DORF
DORP DORQ DORR
DORY wherein * is the Labeling position.
20. The method of use according to claim 17, wherein the carbon-isotope is 11/ C, 13C, or 14C.
21. The method of use according to claim 17, wherein the carbon-isotope is 11/ C.
22. The method of use according to claim 17, wherein the palladium mediated carbonylation reaction is represented by scheme (1):
Scheme (1) wherein the concentration of the carbon-isotope monoxide is about ca 10"2 M to about ca 10'6 M.
23. The method of use according to claim 17, wherein the concentration of the carbon isotope monoxide is about ca 10"4 M.
24. The method of use according to claim 17, wherein the resulting solution is a purified product.
25. The method of use according to claim 17, wherein the liquid chromatograph is semi-preparaitive.
26. A method of use for labeling synthesis of precursor amines for N-(2,5- dimethoxybenzyl)-iV-(5-fluoro-2-phenoxyphenyl) acetamide analogues, comprising the reaction performed by Scheme (2):
R1 = OMe, Cl, H
X = F, Cl, H Y = Br, Cl R2 = H, OMe R3 = H, OMe wherein Rl is OMe, F, or hydrogen; R2 is hydrogen or OMe; and R3 is hydrogen or OMe
Scheme (2).
27. A method of use for labeling synthesis of precursors for N-(2,5- dimethoxybenzyl)-N-(5-fluoro-2-phenoxyphenyl) acetamide analogues, comprising the reaction performed by Scheme (3):
Scheme (3).
28. A method of use for labeling synthesis of precursors for N-(2,5- dimethoxybenzyl)-iV-(5-fluoro-2-phenoxyphenyl) acetamide analogues, comprising the reaction performed by Scheme (4):
8
R1 = OMe or H R2 = OMe or H R3 = Ome or H wherein Rl is OMe or hydorgen; R2 is OMe or hydrogen; and R3 is OMe or hydrogen
Scheme (4).
29. A method of use for labeling synthesis of reference compounds for N-(2,5- dimethoxybenzyl)-N-(5-fluoro-2-phenoxyphenyl) acetamide analogues, comprising the reaction performed by Scheme (5):
10 11
X = F, Cl wherein X is F or Cl
Scheme (5).
30. The method for labeling synthesis of precursor amines according to claim 26, wherein the precursor amines are represented by one or more of the following compounds:
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US72191805P | 2005-09-29 | 2005-09-29 | |
| US60/721,918 | 2005-09-29 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO2007036785A2 true WO2007036785A2 (en) | 2007-04-05 |
| WO2007036785A3 WO2007036785A3 (en) | 2007-08-30 |
Family
ID=37820574
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/IB2006/002669 Ceased WO2007036785A2 (en) | 2005-09-29 | 2006-09-26 | Carbon-isotope monoxide labeling of daa1106 and its analogues to be used as tracers for a peripheral type benzodiazepine binding site |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO2007036785A2 (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007074383A1 (en) * | 2005-12-28 | 2007-07-05 | Ge Healthcare Limited | 18f-labeled phenoxyphenyl n-benzyl alkanamid derivatives for positron emission tomography (pet) imaging of peripheral benzodiazepine receptor |
| CN101830766A (en) * | 2010-04-29 | 2010-09-15 | 金华双宏化工有限公司 | Synthesis method of amino aromatic ether compound |
| WO2010106166A2 (en) | 2009-03-19 | 2010-09-23 | Ge Healthcare Limited | Aryloxyanilide derivatives |
| WO2011073304A1 (en) | 2009-12-17 | 2011-06-23 | Ge Healthcare Limited | Aryloxyanilide imaging agents |
-
2006
- 2006-09-26 WO PCT/IB2006/002669 patent/WO2007036785A2/en not_active Ceased
Non-Patent Citations (5)
| Title |
|---|
| "Aldrich- Handbook of Fine Chemicals and Laboratory Equipment" 2003, ALDRICH , XP002424786 page 178, B1,790-6: benzyl bromide * |
| FARHAD KARIMI ET AL.: "Synthesis of 11C-amides using [11C]carbon monoxide and in situ activated amines by palladium-mediated carboxaminations" ORG. BIOMOL. CHEM., no. 1, 2003, pages 541-546, XP002383785 * |
| LAB CHIP, vol. 4, 2004, pages 523-525, XP002424707 Syntheses of 11C- and 18F-labeled carboxylic esters within a hydrodynamically-driven micro-reactor * |
| TAKETOSHI OKUBO ET AL.: "Design, synthesis and structure-affinity relationships of aryloxyanilide derivatives as novel peripheral benzodiazepine receptor ligands" BIOORGANIC AND MEDICINAL CHEMISTRY, vol. 12, 2004, pages 423-438, XP002424709 * |
| ZHANG M-R ET AL: "[<11>C]DAA1106: radiosynthesis and in vivo binding to peripheral benzodiazepine receptors in mouse brain" NUCLEAR MEDICINE AND BIOLOGY, ELSEVIER, NY, US, vol. 30, no. 5, May 2003 (2003-05), pages 513-519, XP004433738 ISSN: 0969-8051 * |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007074383A1 (en) * | 2005-12-28 | 2007-07-05 | Ge Healthcare Limited | 18f-labeled phenoxyphenyl n-benzyl alkanamid derivatives for positron emission tomography (pet) imaging of peripheral benzodiazepine receptor |
| WO2010106166A2 (en) | 2009-03-19 | 2010-09-23 | Ge Healthcare Limited | Aryloxyanilide derivatives |
| WO2011073304A1 (en) | 2009-12-17 | 2011-06-23 | Ge Healthcare Limited | Aryloxyanilide imaging agents |
| CN101830766A (en) * | 2010-04-29 | 2010-09-15 | 金华双宏化工有限公司 | Synthesis method of amino aromatic ether compound |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2007036785A3 (en) | 2007-08-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101913973B (en) | Preparation and use of alkylating agents | |
| Talukdar et al. | Low Valent Titanium Mediated Imino− Pinacol Coupling: An Improved and Expeditious Route to Vicinal Diamino-Based Ligands | |
| JP2022136074A (en) | Novel formulations and synthetic methods | |
| WO2007132689A1 (en) | Process for production of radioactive fluorine-labeled organic compound | |
| EP2334642B1 (en) | Simplified one-pot synthesis of [18f]sfb for radiolabeling | |
| Dahl et al. | Radiosynthesis of a Bruton's tyrosine kinase inhibitor,[11C] Tolebrutinib, via palladium‐NiXantphos‐mediated carbonylation | |
| CA2629227C (en) | Precursor compound of radioactive halogen-labeled organic compound | |
| Eriksson et al. | Synthesis of [11C]/[13C] acrylamides by palladium‐mediated carbonylation | |
| KR20120034724A (en) | Usage of low to medium-pressure liquid chromatography for the purification of radiotracers | |
| JP5594742B2 (en) | 18F labeled azide compound, 18F labeling reagent, and 18F labeling method for alkyne compound using the same | |
| TWI410396B (en) | A new method for the production of organic compounds and the use of the compounds for radioactive halogen calibration of organic compounds | |
| WO2007036785A2 (en) | Carbon-isotope monoxide labeling of daa1106 and its analogues to be used as tracers for a peripheral type benzodiazepine binding site | |
| Wester | 42 18 F: Labeling Chemistry and Labeled Compounds | |
| Koslowsky et al. | Synthesis and application of 4-[18F] fluorobenzylamine: a versatile building block for the preparation of PET radiotracers | |
| EP2978456B1 (en) | Radiolabelling process | |
| Ross et al. | 18F: Labeling chemistry and labeled compounds | |
| JP6770837B2 (en) | Method for Producing Radioactive Fluorine Labeled Organic Compounds | |
| Rahman et al. | Synthesis of N‐(2, 5‐dimethoxybenzyl)‐N‐(5‐fluoro‐2‐phenoxyphenyl)[carbonyl‐11C] acetamide ([carbonyl‐11C] DAA1106) and analogues using [11C] carbon monoxide and palladium (0) complex | |
| CN113105432B (en) | A carbon-11 (11C) radiopharmaceutical and its preparation method and application | |
| Roslin et al. | Reaction of 11C‐benzoyl chlorides with metalloid reagents: 11C‐labeling of benzyl alcohols, benzaldehydes, and phenyl ketones from [11C] CO | |
| Thonon et al. | Photoactivated 1, 3-dipolar cycloaddition for the rapid preparation of 18F labelled radiotracers | |
| US8076464B2 (en) | Methods for carbon isotope labeling synthesis of ketones and amines by Suzuki coupling reactions using carbon-isotope monoxide | |
| EP1934160B1 (en) | Method for the use of [11c]carbon monoxide in labeling synthesis of 11c-labelled ketones by photo-induced free radical carbonylation | |
| WO2005061445A1 (en) | Methods for carbon isotope labeling synthesis by rhodium-promoted carbonylation via isocyanate using azides and carbon-isotope monoxide | |
| Antoni et al. | 11C: labeling chemistry and labeled compounds |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| NENP | Non-entry into the national phase in: |
Ref country code: DE |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 06820759 Country of ref document: EP Kind code of ref document: A2 |